Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma

Supplemental materials for: Micallef et al

Additional participating institutions:
Carle Cancer Center CCOP, Urbana, IL 61801 (Kendrith M. Rowland, Jr, M.D.)
Meritcare Hospital CCOP, Fargo, ND 58122 (Preston D. Steen, M.D.)
Iowa Oncology Research Association, Des Moines, IA 50309 (Robert J. Behrens, M.D.)
Colorado CCOP, Columbus, OH 53215 (Eduardo R. Pajon, Jr., M.D.)
Hematology & Oncology of Dayton, Inc., Dayton, OH 45415 (Howard M. Gross, M.D.)
Mayo Clinic Florida, Jacksonville, FL 32224 (Edith A Perez, M.D.)
Mayo Clinic Arizona, Scottsdale, AZ 85259-5404 (Tom R. Fitch, M.D.)
Lehigh Valley Hospital, Allentown, PA 18103 (Suresh Nair, M.D.)
Abbott Northwestern Hospital, Minneapolis, MN 55407 (Daniel M. Anderson, M.D.)
Sioux Community Cancer Consortium, Sioux Falls, SD 57105 (Loren K. Tschetter, M.D.)
Illinois Oncology Research Assn. CCOP, Peoria, IL 61615-7828 (John W. Kugler, M.D.)
Rapid City Regional Oncology Group, Rapid City, SD 57709 (Richard C. Tenglin, M.D.)
CentraCare Clinic, St. Cloud, MN 56301 (Donald Jurgens, M.D.)
Siouxland Hematology-Oncology Associates, Sioux City, IA 51105 (Donald B. Wender, M.D.)
Cancer Care Associates, Tulsa, OK 74136 (Alan Keller, M.D.)
Upstate Carolina CCOP, Spartanburg, SC 29303 (James D. Bearden, III, M.D.)